

Presentations
LC-MS/MS Matrix Effects - Mechanisms, Sources, Evaluation and Strategies to Minimize,
Donald L. Reynolds, Invited Speaker, Lotus Clinical Research Academy, Bangalore, India,
October 2007.
LC-MS/MS Matrix Effects - Mechanisms, Sources, Evaluation and Strategies to Minimize,
Donald L. Reynolds, Invited Speaker, Lotus Labs Pvt. Ltd., Bangalore, India, September
2007.
HPLC Column Switching – Introduction and Selected Applications, Donald L. Reynolds,
Invited Speaker, Lotus Labs Pvt. Ltd., Bangalore, India, July 2007.
Introduction to Bioanalysis, Donald L. Reynolds, Invited Speaker, Lotus Clinical Research
Academy, Bangalore, India, April, July, September and October 2007.
Approaches to Bioanalytical Method Development - Strategies and Applications, Donald L.
Reynolds, Invited Speaker, Lotus Clinical Research Academy, Bangalore, India, April, July,
September and October 2007.
Influence of Silanol Interactions on the Retention of Amine-Containing Analytes on
Silica-Based Bonded Phases – Column Chemistry and Selection of the Right Column, Donald
L. Reynolds, Invited Speaker, Lotus Clinical Research Academy, Bangalore, India, April,
July, September and October 2007.
Extraction Considerations for the Development of Robust Methods, Donald L. Reynolds,
Invited Speaker, Lotus Clinical Research Academy, Bangalore, India, April, July, September
and October 2007.
Extraction Development - Considerations for Developing Robust Extraction Methodology,
Donald L. Reynolds, Invited Speaker, Lotus Labs Pvt. Ltd., Bangalore, India, March 2007.
Influence of Silanol Interactions on the Retention of Amine-Containing Analytes on
Silica-Based Bonded Phases, Donald L. Reynolds, Invited Speaker, Lotus Labs Pvt. Ltd.,
Bangalore, India, March 2007.
Strategy for Developing Bioanalytical Methods for Marketed Products, Donald L. Reynolds,
Invited Speaker, Lotus Labs Pvt. Ltd., Bangalore, India, December 2006.
Bioanalytical Method Development - Strategies and Applications, Donald L. Reynolds, Invited
Speaker, Lotus Labs Pvt. Ltd., Bangalore, India, November 2006.
Bioanalytical Case Studies, Donald L. Reynolds, Invited Speaker, Panacos Pharmaceuticals,
Gaithersburg, MD, May 2004.
Bioanalytical Case Studies, Donald L. Reynolds, Invited Speaker, Ricerca Biosciences,
Concord, OH, February 2004.
Design and Implementation of a Fully Tunable UV/VIS Solid-State Laser-Induced
Fluorescence (LIF) Detection System for HPLC Analysis, Donald L. Reynolds, US Bioanalytics
Department Seminar, Hoechst Marion Roussel, Kansas City, MO, December 1998.
Design and Implementation of a Fully Tunable UV/VIS Solid-State Laser-Induced
Fluorescence (LIF) Detection System for HPLC Analysis, Donald L. Reynolds, Invited
Speaker, American Association of Pharmaceutical Scientists Annual Meeting, San Francisco,
CA, November 1998.
Bioanalytical Case Studies, Donald L. Reynolds, Invited Speaker, Pharmaceutical Analysis II
Class, The University of Kansas, Department of Pharmaceutical Chemistry, Lawrence, KS,
October 1997.
Generalized Strategy for Developing Solid Phase Extraction Methods, Donald L. Reynolds,
Invited Speaker, The Strategic Method Development Workshop, Marion Merrell Dow, Inc.,
Kansas City, MO, December 1994.
The Isomeric Separation of Beraprost Sodium Using an -1-Acid Glycoprotein Column, T.
A. Walker, L. A. Sly and D. L. Reynolds, 4th International Symposium on Chiral
Discrimination, Montreal, Canada, September 1993.
Development of a Chiral Separation of Beraprost Sodium Using an -1-Acid Glycoprotein
Column, L. A. Sly, T. A. Walker and D. L. Reynolds, American Association of Pharmaceutical
Scientists Annual Meeting, San Antonio, TX, November 1992.
Development of a Chiral Separation of Beraprost Sodium Using an -1-Acid Glycoprotein
Column, L. A. Sly, T. A. Walker and D. L. Reynolds, Midwest Regional ACS Meeting,
Lawrence, KS, November 1992.
Development of a Chiral Separation of Beraprost Sodium Using an -1-Acid Glycoprotein
Column, L. A. Sly, T. A. Walker and D. L. Reynolds, HPLC-92, Baltimore, MD, June 1992.
A Validated Liquid Chromatographic Assay to Quantitate ML-1012 in Human Plasma at
Femtomole Levels, D. L. Reynolds, L. S. Eichmeier and D. H. Giesing, Development
Resources Scientific Conference, Marion Merrell Dow, Inc., Kansas City, MO, November
1991.
Strategies for Bioanalytical Methods Development, Donald L. Reynolds, Invited Speaker,
Department of Pharmaceutical Chemistry Seminar, The University of Kansas, Lawrence, KS,
October 1991.
A Validated Liquid Chromatographic Assay to Quantitate ML-1012 in Human Plasma at
Femtomole Levels, D. L. Reynolds, L. S. Eichmeier and D. H. Giesing, 3rd International
Symposium on Pharmaceutical and Biomedical Analysis, Boston, MA, April 1991.
Generalized Strategy for Developing Solid Phase Extraction Methods, Donald L. Reynolds,
Invited Speaker, Kansas City Chromatography Discussion Group, Kansas City, MO, July 1990.
Validated Liquid Chromatographic Assay for the Antiallergy Agent CI-949 in Rat, Dog and
Human Plasma, D. L. Reynolds, K. L. Hoffman and L. A. Pachla, American Association of
Pharmaceutical Scientists Annual Meeting, Orlando, FL, October 1988.
Using Robotics in Pharmacokinetic Studies – Help or Hindrance?, Elvin L. Johnson, Keith L.
Hoffman, Donald L. Reynolds and Larry A. Pachla, Eastern Analytical Symposium, New York,
NY, October 1988.
Application of Robotics for the Unattended Development of Liquid-Solid Extractions and
Routine Analysis of Biological Samples, D. L. Reynolds*, E. L. Johnson, K. L. Hoffman and L.
A. Pachla, *Invited Speaker, American Midwest Regional Association of Pharmaceutical
Scientists Meeting, Chicago, IL, May 1988.
Robotic Technology Applied to Pharmacokinetic/Drug Metabolism Studies, Elvin L. Johnson,
Donald L. Reynolds and Lawrence A. Pachla, 10th International Symposium on Column Liquid
Chromatography, San Francisco, CA, May 1986.
Use of a Chronic Intraduodenal Cannula Preparation for Two-Week Toxicity Studies in Rats,
Robert Bonczyk, Michelle Roth, Barbara Windsor, Irene Eiseman, Donald Reynolds and Tsun
Chang, FASEB, St. Louis, MO, April 1986.
Validated HPLC Analysis of the Antiallergy Agent CI-922, I. A. Eiseman, E. L. Johnson, L. A.
Pachla, D. L. Reynolds and P. G. Welling, Academy of Pharmaceutical Sciences Annual
Meeting, Minneapolis, MN, October 1985.
Analysis of the New Bronchodilator 3-[2-(Ethylamino)-propyl]-1,2,3,4-tetrahydro-5H-(1)-
benzopyrano(3,4-c)pyridin-5-one (CI-923) in Plasma by Liquid Chromatography Following
Derivatization with Fluorescein-6-Isothiocyanate (F6ITC), Donald L. Reynolds and Lawrence
A. Pachla, Academy of Pharmaceutical Sciences Annual Meeting, Philadelphia, PA, October
1984.
The Retention Behavior of Quaternary and bis-Quaternary Ammonium Compounds in
Reversed-Phase HPLC Systems, Donald L. Reynolds, A. J. Repta and L. A. Sternson,
Academy of Pharmaceutical Sciences Annual Meeting, San Diego, CA, November 1982.
The Retention Behavior of Quaternary and bis-Quaternary Ammonium Compounds in
Reversed-Phase HPLC Systems, D. L. Reynolds, A. J. Repta and L. A. Sternson, 6th
International Symposium on Column Liquid Chromatography, Cherry Hill, NJ, June 1982.
The Effects of Temperature and Ion Pairing on the HPLC Behavior of the Antineoplastic
Agent DHAD (NSC 301739), Donald L. Reynolds, L. A. Sternson and A. J. Repta, Academy of
Pharmaceutical Sciences Annual Meeting, San Antonio, TX, November 1980.
Donald L. Reynolds, PhD & Associates, Inc. • 436 NW Highcliffe Dr. • Lee’s Summit, MO 64081 © Copyright 2007 All Rights Reserved Donald L. Reynolds, PhD & Associates, Inc Web Design by www.photographybytuckdesigns.com.
|
DONALD L. REYNOLDS PHD & ASSOCIATES, INC.
|
Bioanalytical / Pharmaceutical Consulting Services
PhD & Associates, Inc.